EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 康健國際醫療集團有限公司 | | 股份代號 | 03886 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止末期股息 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.0018 HKD | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.0018 HKD | | 匯率 | 1 HKD : ...

Financial Performance - The group recorded revenue of approximately HKD 1,785,563,000, a decrease of 2.6% from HKD 1,833,795,000 in the previous year[4] - The net profit for the year was approximately HKD 64,800,000, compared to a net loss of HKD 158,207,000 in the previous year[4] - Operating profit for the year, excluding other income and losses, was approximately HKD 87,501,000, an increase of 23.5% from HKD 70,855,000 in the previous year[4] - The total comprehensive income for the year was HKD 96,101,000, a significant recovery from a loss of HKD 223,576,000 in the previous year[6] - The group reported a basic and diluted earnings per share of HKD 0.21, compared to a loss per share of HKD 3.01 in the previous year[6] - The group proposed a final dividend of HKD 0.18 per share, up from HKD 0.12 per share in the previous year[3] Assets and Liabilities - The group's total assets amounted to approximately HKD 3,398,824,000, slightly up from HKD 3,380,347,000 in the previous year[4] - The debt ratio decreased to 0.36% from 2.71% in the previous year, reflecting improved financial leverage[4] - The group's current assets net value was approximately HKD 1,329,944,000, compared to HKD 1,300,647,000 in 2024, with a current ratio of 3.64, up from 3.19 in 2024[88] - The group has pledged assets valued at approximately HKD 28,340,000 as of December 31, 2025, a decrease from HKD 120,545,000 in 2024[94] Revenue Breakdown - Total revenue for the year was HKD 1,777,879,000, a decrease of 2.5% from HKD 1,823,021,000 in the previous year[18] - Revenue from Hong Kong medical services was HKD 731,898,000, down from HKD 787,053,000, representing a decline of 7.0%[16] - Revenue from mainland China hospital management and medical services increased to HKD 584,884,000, up from HKD 546,615,000, reflecting a growth of 7.0%[16] - The group reported a total segment revenue of HKD 1,785,563,000, with external sales contributing HKD 1,785,563,000 and inter-segment sales of HKD 35,577,000[22] Operational Efficiency and Strategy - The company aims to enhance operational efficiency and optimize patient experience in response to the challenging economic environment[50] - The group continues to optimize its network layout in Hong Kong to enhance operational efficiency and resource effectiveness, including the establishment of multi-clinic centers[57] - The introduction of telemedicine services and a mobile app aims to improve accessibility and efficiency in healthcare delivery, with services available seven days a week[60] - The group is focusing on optimizing service processes through technology, including the introduction of WhatsApp appointment services to enhance customer experience[63] Future Projections and Plans - The group’s total revenue for the fiscal year ending December 31, 2025, is projected to be HKD 1,773,165,000 under the gross basis accounting method[19] - The company plans to enhance operational efficiency and resource allocation to reduce healthcare service costs while improving overall medical experience[82] - A new multi-clinic "Health Comprehensive Medical Center" will be established in North Point, Hong Kong, to provide convenient and efficient one-stop medical services[82] Governance and Compliance - The company has adopted its own corporate governance code in accordance with the principles and provisions of the corporate governance code this year[103] - The roles of the Chairman and CEO are held by the same individual, Mr. Choi Ka-Chan, which deviates from the code but is believed to ensure consistent leadership and operational efficiency[104] - The auditor, Deloitte Touche Tohmatsu, has been reappointed at the annual general meetings held from 2018 to 2025[106] Market and Industry Trends - The healthcare industry in mainland China is undergoing a deep transformation, with a focus on high-quality development and the allocation of quality medical resources[51] - The demand for primary healthcare, specialist treatment, health management, and rehabilitation services is expected to continue growing due to an aging population and increased health awareness[81] Employee and Operational Metrics - The total employee cost for the year was approximately HKD 706,701,000, down from HKD 743,697,000 in 2024, with 1,345 employees as of December 31, 2025[92] - The group has identified four operating and reporting segments: Hong Kong medical services, Hong Kong medical network management, mainland China hospital management and medical services, and others[20]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Town Health International Medical Group Limited 康健國際醫療集團有限公司 （於開曼群島註冊成立及於百慕達存續之有限公 司） 康健國際醫療集團有限公司 主席兼行政總裁 蔡加讚， 金紫荊星章，太平紳士 香港，二零二六年三月十七日 於本公告日期，本公司執行董事為蔡加讚先生， 金紫荊星章，太平紳士 （主席兼行政 總裁）、霍兆榮醫生、張霄雪女士及黃宇先生；本公司非執行董事為李蕙苓女士、 劉淑卿女士、劉陽先生及張蕾娣女士；而本公司獨立非執行董事為于學忠先生、 徐衛國博士、韓文欣先生、陳偉根先生、張加銘先生及崔永昌先生。 （股份代 號：3886） 董事會會議召開日期 康健國際醫療集團有限公司（「本公司」）之董事會（「董事會」）宣佈，董事會會議將於 二零二六年三月二十七日（星期五）舉行，藉以（其中包括）批准本公司及其附屬公司 截至二零二五年十二月三十一日止年度之末期業績，以 ...

Town Health International Medical Group Limited 康健國際醫療集團有限公司 司） （於開曼群島註冊成立及於百慕達存續之有限公 （股份代 號：3886） 正面盈利預告 康健國際醫療集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）乃根據香港 法例第571章證券及期貨條例第XIVA部項下之內幕消息條文及香港聯合交易所有限 公司證券上市規則第13.09(2)條發出本公告。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 倘排除於綜合損益表中所示的「其他收益及虧損淨額」後，本集團預期截至二零二五 年十二月三十一日止年度，就其業務經營將錄得介乎約61,300,000港元至96,300,000 港元之經營溢利，當中包括介乎26,500,000港元至41,600,000港元之股東應佔經營溢 利，而於截至二零二四年十二月三十一日止年度，則錄得經營溢利約70,900,000港 元，當中包括股東應佔經營溢利約25,400 ...

截至月份: 2026年2月28日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 康健國際醫療集團有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03886 | 說明 | 康健國際醫療 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,0 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康健國際醫療集團有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 本月底法定/註冊股本總額： HKD 303,750,000 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03886 | 說明 | 康健國際醫療 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 6,773,522,452 | | 0 | | 6,773,522,452 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康健國際醫療集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03886 | 說明 | 康健國際醫療 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 HKD | | 300,000,000 | | 2. 股份分類 ...

Town Health International Medical Group Limited 康健國際 醫 療 集 團 有限公司 （ 於 開 曼 群 島 註 冊 成 立 及 於 百 慕 達 存 續 之 有 限 公 司 ） （ 股份代號 ： 3 8 8 6 ） （ 「 本 公 司 」 ） 提名委員會之職權範圍 （生效日期：2026 年 1 月 1 日） 1. 目標 提名委員會（「委員會」）負 責 向 本公 司 董事 會（「董事會」）建議委任本公司的董 事（「董事」），以確保所有提名屬公平及具透明度。 2. 組成 3. 會議 2.1 委員會須由董事會委任，並由最少三名成員組成。當中大部分成員須為本 公司的獨立非執行董事。委員會至少一名成員須為不同性別的成員。 2.2 委員會的主席須由董事會委任，並須為董事會主席或獨立非執行董事。 2.3 委員會的秘書須由本公司的公司秘書擔任，秘書必須確保所有會議均能 保存完整的會議記錄。 3.1 委員會舉行的會議和會議議程，須受本公司細則關於董事會會議和議程 的適用條文所管轄。 3.2 委員會每年須舉行至少一次會議，並於有需要時或任何委員會成員要求 時舉行會議。委員會會議的法定 ...

Core Viewpoint - The article highlights the launch of a public respiratory health education project by 康健国际医疗 in collaboration with Pfizer Hong Kong and Tung Wah Group of Hospitals, aimed at enhancing community health protection against respiratory diseases, particularly pneumonia, during the high-risk winter season [1][2]. Group 1: Project Overview - 康健国际医疗, Pfizer Hong Kong, and Tung Wah Group of Hospitals have established a collaborative framework to enhance public health education and provide accessible vaccination services [2]. - The project includes a donation of 20-valent pneumococcal conjugate vaccines to support vulnerable communities, aligning with the Hong Kong Department of Health's "prevention first" strategy [1][2]. Group 2: Health Statistics and Risks - Pneumonia is the second leading cause of death in Hong Kong, with over 11,000 deaths projected in 2024, highlighting the urgent need for preventive measures [2]. - The pneumococcus bacterium poses significant treatment challenges due to increasing antibiotic resistance, necessitating a focus on prevention [4]. Group 3: Vaccine Details - The donated 20-valent pneumococcal conjugate vaccine covers 20 serotypes, including seven newly added types associated with high mortality and antibiotic resistance [2]. - A single dose of the vaccine provides broad protection, particularly for high-risk groups such as the elderly and those with chronic illnesses [2]. Group 4: Community Impact - The initiative addresses health protection gaps for economically disadvantaged and mobility-impaired individuals, ensuring equitable access to vaccination [4]. - The project aims to shift public health perspectives from treatment-focused to prevention-oriented approaches, enhancing community awareness of pneumonia risks and vaccine benefits [5]. Group 5: Collaborative Model - The partnership exemplifies a successful integration of commercial healthcare services, pharmaceutical expertise, and community outreach, creating a comprehensive prevention and support system [5]. - This model serves as a replicable framework for future public health initiatives, potentially alleviating the overall burden on Hong Kong's public healthcare system [5].

Core Viewpoint - The article highlights the launch of a public respiratory health education project by 康健国际医疗 in collaboration with Pfizer Hong Kong and Tung Wah Group of Hospitals, aimed at enhancing community health protection against respiratory diseases, particularly pneumonia, during the high-risk winter season [1][2]. Group 1: Project Overview - The initiative is a response to the Hong Kong Department of Health's "Primary Healthcare Blueprint," promoting a shift from treatment-focused to prevention-oriented health concepts [2]. - 康健国际医疗 will coordinate public health education and provide vaccination services through its extensive network, while Pfizer will supply the 20-valent pneumococcal conjugate vaccine and medical expertise [2]. - Tung Wah Group of Hospitals will identify and assist vulnerable communities to ensure effective vaccine distribution and administration [2]. Group 2: Health Statistics and Vaccine Details - Pneumonia is the second leading cause of death in Hong Kong, with over 11,000 deaths projected in 2024, making it a significant public health concern [3]. - The 20-valent pneumococcal conjugate vaccine covers 20 serotypes, including seven newly added types associated with high mortality and antibiotic resistance, requiring only one dose for broad protection [3]. Group 3: Community Impact and Collaboration - The project addresses the urgent need for respiratory health education, particularly for the elderly and vulnerable populations, who face higher infection risks [4]. - The collaboration aims to fill the health protection gap for economically disadvantaged groups, allowing them to receive the vaccine for free [5]. - The initiative exemplifies a comprehensive approach to public health, integrating commercial healthcare services, pharmaceutical expertise, and community outreach to enhance the effectiveness of health interventions [6]. Group 4: Health Awareness and Future Implications - The project promotes a shift in public health perception from treatment to prevention, enhancing community awareness of pneumonia risks and the value of vaccination [6]. - The collaboration model serves as a reference for future public health initiatives, potentially applicable to chronic disease management and other infectious disease control efforts [6].